论文部分内容阅读
目的探讨纳洛酮治疗Ⅱ型呼吸衰竭临床疗效。方法选择慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭患者86例,随机分为2组:治疗组应用纳洛酮0.8 mg加入5%葡萄糖注射液20 ml中静脉注射,然后将1.2 mg纳洛酮加入5%葡萄糖注射液250 ml中以0.4～0.8 mg/h的速度静脉滴注;对照组每日用尼可刹米1.875～3.75 g加入5%葡萄糖注射液250～500 ml中静脉滴注维持,疗程7 d。结果治疗组总有效率为88.6%,对照组总有效率为52.3%,2组总有效率比较差异有统计学意义(P<0.01)。结论纳洛酮能兴奋呼吸中枢,改善缺氧和CO2潴留,治疗Ⅱ型呼吸衰竭安全有效。
Objective To investigate the clinical effect of naloxone on type Ⅱ respiratory failure. Methods Eighty-six patients with chronic obstructive pulmonary disease (COPD) and type Ⅱ respiratory failure were randomly divided into two groups: the treatment group was given intravenous injection of naloxone (0.8 mg) and 20 ml of 5% glucose injection (20 mg) Ketorolac was added into 250 ml of 5% glucose injection at a rate of 0.4-0.8 mg / h, while in the control group, intravenous drip of 250-500 ml of 5% dextrose injection (1.875-3.75 g) Note maintenance, treatment 7 d. Results The total effective rate was 88.6% in the treatment group and 52.3% in the control group. The total effective rate in the two groups was significantly different (P <0.01). Conclusion Naloxone can excite the respiratory center, improve hypoxia and CO2 retention, and treat type II respiratory failure safely and effectively.